Hyperbaric oxygen and postradiation osteonecrosis of the mandible |
| |
| Affiliation: | 1. Division of Radiation Oncology, B.C. Cancer Agency, Vancouver Clinic, 600 West 10th Avenue, Vancouver, B.C., Canada V5Z 4E6;2. Department of Dentistry, B.C. Cancer Agency, Vancouver Clinic, 600 West 10th Avenue, Vancouver, B.C., Canada V5Z 4E6;3. Hyperbaric Unit, Vancouver General Hospital, Vancouver, British Columbia, Canada;1. Department of Haematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan;2. School of Medicine, Fujita Medical University, Toyoake, Japan;3. Hematology Department, The Catalan Institute of Oncology–The Josep Carreras Leukaemia Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain;4. Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St Mary''s Hospital, The Catholic University of Korea, Seoul, South Korea;5. Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan;6. Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan;7. Division of Hematology and Bone Marrow Transplantation, N N Blokhin Russian Cancer Research Center, Moscow, Russia;8. Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea;9. Northern Institute for Cancer Care, Newcastle University, Newcastle-upon-Tyne, UK;10. Department of Onco-Hematology, Portuguese Institute of Oncology, Porto, Portugal;11. Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, St Petersburg, Russia;12. Department of Haematology, Jagiellonian University, Kraków, Poland;13. Department of Hematology, Hospital Arnau de Vilanova, Valencia, Spain;14. Department of Hematology, Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia;15. N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Belarus;p. Department of Internal Medicine, Universidad de la Frontera, Temuco, Chile;q. Department of Medicine, Charles University, General Hospital in Prague, Prague, Czech Republic;r. Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA;s. Department of Hematology, Hospices Civils de Lyon, Lyon, France;t. Comprehensive Cancer Center Ulm, University Hospital of Ulm, Ulm, Germany;u. Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;v. Celltrion, Inc., Incheon, South Korea;1. Service pharmacie clinique, hôpital universitaire Necker–Enfants-Malades, 149, rue de Sèvres, 75015 Paris, France;2. Service pharmacie clinique, hôpital Jean-Verdier, hôpitaux universitaires de Paris-Seine-Saint-Denis, Bondy, France;3. Service radiologie, hôpital Jean-Verdier, hôpitaux universitaires de Paris-Seine-Saint-Denis, Bondy, France;1. Waterbury Hospital, United States;2. Duke University, United States;3. Centers for Disease Control, United States;4. Yale University, United States;1. Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA;2. Department of Neurology, Harvard Medical School, Boston, MA, USA;3. Department of Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, 513 parnassus avenue, health science suite 814, San Francisco, CA 94143, USA;4. Department of Neurology, Mayo Clinic Cancer Center, 5777 E. Mayo Blvd, Phoenix, AZ 85054, USA;1. Division of Hematology-Oncology, Milton S. Hershey Cancer Institute, Penn State University, Hershey, PA;2. Department of Pathology, Milton S. Hershey Cancer Institute, Penn State University, Hershey, PA |
| |
| Abstract: | The clinical and dental records of 26 patients with the clinical diagnosis of postradiation osteonecrosis (PRON) managed with hyperbaric oxygen (HBO) were reviewed to determine the efficacy of HBO. 19 patients were male and 7 were female; age at the first HBO session ranged from 28 to 80 years (median 57.5 years). All but 8 patients reviewed had some form of surgical management; 7 had mandibulectomy for PRON. As part of management, a total of 9–84 HBO sessions (median 35 sessions) was administered. 18 of the 26 patients ultimately achieved persistent mucosal and cutaneous coverage 1–84 months (median 24 months) after the first HBO session. 13 of the 26 patients met strict criteria for resolution of their disease; fully 21 of 26 patients had improved PRON status following HBO therapy. HBO treatment as part of a comprehensive managment plan is safe and effective in the management of PRON. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
